Research Progress on Glypican-3 Targeted Therapy in Hepatocellular Carcinoma / 药学实践杂志
Journal of Pharmaceutical Practice
;
(6): 586-593, 2023.
Artículo
en Chino
| WPRIM
| ID: wpr-996915
ABSTRACT
Liver cancer is the second leading cause of cancer-related deaths worldwide, with hepatocellular carcinoma (HCC) being the most common form of primary liver cancer. Glypican-3 (GPC3) is a cell membrane proteoglycan which is rarely expressed in normal adult tissues but is specifically upregulated in HCC, which makes GPC3 a reliable target for the diagnosis and treatment of HCC. The role of GPC3 in the regulation of cancer development through Wnt, YAP, hedgehog and other signaling pathways were reviewed in this article. GPC3-targeted therapies, such as monoclonal antibodies, bispecific antibodies, tumor vaccines, immunotoxins, CAR-T cells, and photosensitizer therapy were also summarized. These treatment methods offered promising approaches for HCC treatment and future treatment strategies for HCC based on GPC3 were prospected in this paper.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Idioma:
Chino
Revista:
Journal of Pharmaceutical Practice
Año:
2023
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS